1Y Close · As of Aug 26, 2026
Vaxcell-Bio Therapeutics operates in the Professional Services sector.
Legal name: Vaxcell-Bio Therapeutics
In fiscal year 2025, Vaxcell-Bio Therapeutics (323990) reported revenue of 7.1 billion KRW, up 271.6% from 1.9 billion KRW a year earlier.
Operating profit was -15.5 billion KRW and net income was -13.3 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 92.7 billion KRW, with a P/B of 1.52.
These figures can be verified in the DART filing (receipt no. 20260316001459).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 7.1B | -15.5B | -13.3B |
| 2024 | 1.9B | -15.0B | -10.6B |
| 2023 | 14M | -11.5B | -10.3B |
Checks
1 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-14 | Semi-Annual Report (2026.06) |